ClinicalTrials.gg
CompletedNCT04346888Updated Mar 8, 2023

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

A Phase 2 interventional study of HBM9161 Injection (680mg and 340 mg) and Placebos in Myasthenia Gravis, sponsored by Harbour BioMed (Guangzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-03-08.

Sponsored by Harbour BioMed (Guangzhou) Co. Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.

Enrollment
37th of 67
30 · median 40
Started
2020
with 8 others
Phase 2
5 of 88
2 open now
Registered
10th of 88
by date
Lead sponsor
3 of 88
Harbour BioMed (Guangzhou) Co. Ltd.

Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 37th largest by enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2020, is one of 5 in phase 2, and was the 10th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Myasthenia Gravis with a site in China, or all of them as a file.
02

Study summary

Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China

Read the detailed description

This is a multicenter, randomized, double-blind and placebo-controlled study. The investigational drug is HBM9161 injection, and the indication is MG.

The subjects will be randomized to three dose groups (340mg, 680mg and placebo) for a 6 weeks' double-blind treatment period followed by an open-label extension treatment period. The study will investigate the safety, efficacy and pharmacodynamic and pharmacokinetic of HBM9161 in patients with attack of MG in China.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

Keywords

  • MG
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form.
  2. Male or female ≥ 18 years of age.
  3. A female participant is eligible to participate if she is of:

    1. Non- (physically infertile, including women who have been menopausal for 2 years or more);
    2. Childbearing potential, negative serum pregnancy test results at screening visits, and agree to consistently use acceptable and effective methods until 14 days after the final visit.
  4. A male participant must take effective contraception during this clinical trial or their heterosexual partner must take effective contraception.
  5. Meets MGFA myasthenia gravis clinical classification IIa-IVa (includes types IIa, IIb, IIIa, IIIb, and IVa) at the screening visit and at the baseline visit.
  6. Screening and baseline MG-ADL score ≥ 6, and \< 50% of them is from ocular muscle.
  7. Stable background MG treatments at randomization.
  8. Positive serologic test for AChR-Ab or MUSK-Ab at the screening visit and at least 1 of the following:

    1. History of abnormal neuromuscular transmission test demonstrated by sign-fiber-electromyography or repetitive nerve stimulation OR
    2. History of positive edrophonium chloride test OR
    3. Participant has demonstrated improvement in MG signs on oral cholinesterase inhibitors as assessed by the treating physician.

Exclusion criteria

Exclusion Criteria:

  1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody/Fc-fusion biologic for immunomodulation within 6 months prior to screening.
  2. Immunoglobulins given by SC, IV(IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before screening.
  3. Thymectomy performed \< 12 months prior to screening.
  4. Total IgG level \<6g/L (at screening).
  5. Participant has any laboratory abnormality (at screening) that, in the opinion of the investigator, is , has not resolved at baseline, and could jeopardize or would compromise the participant's ability to participate in this study.
  6. Have known disease other than MG that would interfere with the course and conduct of the study (such as uncontrolled thyroid disease).
  7. Have an active infection, a recent serious infection (i.e., requiring injectable antimicrobial therapy or hospitalization) within the 8 weeks prior to screening.
  8. History of or known infection with (HIV), virus (HBV), virus (HCV), or Mycobacterium tuberculosis. Participants must have negative test results for HBV surface antigen, HBV core antibody, HCV antibody, HIV 1 and 2 antibodies and a negative TB test at screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    HBM9161 (680mg and 340 mg)

    Subcutaneous injection; Blinded: HBM9161 680mg; Open-label: HBM9161 340mg;

    Drug: HBM9161 Injection (680mg and 340 mg)

  • Experimental
    HBM9161 (340 mg)

    Subcutaneous injection; Blinded: HBM9161 340mg; Open-label: HBM9161 340mg;

    Drug: HBM9161 Injection (340 mg)

  • Placebo comparator
    Placebo, HBM9161 (340 mg)

    Subcutaneous injection; Blinded: Placebo; Open-label: HBM9161 340mg;

    Drug: Placebos

Interventions

  • DrugHBM9161 Injection (680mg and 340 mg)

    Drug page: HBM9161

    HBM9161 Injection (680mg and 340mg)

  • DrugPlacebos

    Placebo, HBM9161 Injection (340mg)

  • HBM9161 Injection (340 mg)

06

What researchers measure

Primary outcomes

  1. Change in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline to Day 43

    The MG-ADL profile provides an assessment of MG symptom severity and measures 8 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the ADL score. The ADL score can range from 0 (least severe) to 24 (most severe)

    Time frame: 43 days

Secondary outcomes

  1. Change in the Myasthenia Gravis Composite (MGC) score from baseline to Day 43

    The total QMG score is obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity.

    Time frame: 43 days

  2. Change in the Quantitative Myasthenia Gravis (QMG) score from baseline to Day 43

    The QMG test is a standardized quantitative strength scoring system and measures 13 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the QMG score. The QMG score can range from 0 (least severe) to 39 (most severe).

    Time frame: 43 days

  3. Change in the Myasthenia Gravis Quality of Life 15(MG-QoL15r) score from baseline to Day 43

    The MG-QoL 15r scale is a patient-reported score that assesses the patient's perception of impairment and disability and the degree to which the patient tolerates disease manifestations. Each question was graded on a 3-point scale from 0=normal to 2=severe with a score of 0 to 30; the higher score indicates worse MG disease activity

    Time frame: 43 days

  4. Proportion of participants with a decrease on the MG-ADL Score by ≥ 2 points from baseline to Day 43

    Time frame: 43 days

  5. Proportion of participants with an improvement and worse on the MGFA Post-intervention Status (MGFA-PIS) from baseline to Day 43. o Improvement: MGC Score reduce ≥ 3 points o Aggravation: MGC Score increase ≥ 3 points

    Time frame: 43 days

  6. Change in the MG-ADL score from baseline to Day 120

    Time frame: 120 days

  7. Change in the MGC score from baseline to Day 120

    Time frame: 120 days

  8. Change in the QMG score from baseline to Day 120

    Time frame: 120 days

  9. Change in the MG-QoL15r score from baseline to Day 120

    Time frame: 120 days

  10. Proportion of participants with persistent improvement on the MGC score from baseline to Day 120

    Improvement (decrease) in the MGC score by ≥ 3 points for 6 weeks

    Time frame: 120 days

  11. Proportion of participants with persistent improvement on the MG-ADL score from baseline to Day 120

    Improvement (decrease) in the MG-ADL Score by ≥ 2 points for 6 weeks

    Time frame: 120 days

07

Study locations

1 site
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai, China
08

References and documents

Publications

  • Yan C, Duan RS, Yang H, Li HF, Zou Z, Zhang H, Zhou H, Li XL, Zhou H, Jiao L, Chen J, Yin J, Du Q, Lee M, Chen Y, Chen X, Zhao C. Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study. Neurol Ther. 2022 Jun;11(2):815-834. doi: 10.1007/s40120-022-00345-9. Epub 2022 Apr 12. PubMed 35412216 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Aug 2021, 13 months.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2020
First posted
Apr 15, 2020
StartActual
Jul 23, 2020
Primary completionActual
Aug 24, 2021
CompletionActual
Aug 24, 2021
Last update
Mar 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04346888
Lead sponsor
Harbour BioMed (Guangzhou) Co. Ltd.
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Jul 23, 2020
Primary completion
Aug 24, 2021
Completion
Aug 24, 2021
Last update
Mar 8, 2023

Study contacts

Chongbo Zhao
principal investigator · Huashan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion